Shopping Cart
- Remove All
- Your shopping cart is currently empty
AZD 1152 is an orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50= 0.36 nM).1AZD 1152 is converted to AZD 1152-HQPA in plasma. Inhibition of Aurora B results in disruption of spindle checkpoint functions and chromosome alignment, resulting in inhibition of cytokinesis followed by apoptosis.2,3AZD 1152 inhibits tumor xenograft growthin vivo.4,5
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | TBD | 35 days | |
5 mg | TBD | 35 days | |
10 mg | TBD | 35 days | |
25 mg | TBD | 35 days |
Description | AZD 1152 is an orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50= 0.36 nM).1AZD 1152 is converted to AZD 1152-HQPA in plasma. Inhibition of Aurora B results in disruption of spindle checkpoint functions and chromosome alignment, resulting in inhibition of cytokinesis followed by apoptosis.2,3AZD 1152 inhibits tumor xenograft growthin vivo.4,5 |
Molecular Weight | 660.47 |
Formula | C26H33Cl2FN7O6P |
Cas No. | 722543-50-2 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO:PBS(pH 7.2) (1:4): 0.2 mg/mL (0.3 mM), Sonication is recommended. DMSO: 1 mg/mL (1.51 mM), Sonication is recommended. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.